Lennham Pharmaceuticals

Lennham Pharmaceuticals is a privately held life sciences company developing differentiated versions of known compounds using selective deuterium chemistry to improve metabolic and pharmacokinetic properties. The company focuses on deuterated small-molecule programs and highlights pipeline assets including d-Psilocybin, d-Caffeine, and d-Testosterone. Lennham positions its approach as a way to generate products with superior profiles and strong patent protection while leveraging established biology and, in some cases, potential 505(b)(2) development pathways. Its disclosed programs span neuropsychiatric, endocrine, and consumer/pharmaceutical applications. The company is based in Concord, Massachusetts and appears to remain active as of 2026.